EP1986619A4 - Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor - Google Patents

Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Info

Publication number
EP1986619A4
EP1986619A4 EP07763614A EP07763614A EP1986619A4 EP 1986619 A4 EP1986619 A4 EP 1986619A4 EP 07763614 A EP07763614 A EP 07763614A EP 07763614 A EP07763614 A EP 07763614A EP 1986619 A4 EP1986619 A4 EP 1986619A4
Authority
EP
European Patent Office
Prior art keywords
phosphatases
cor
treat tumors
tumors overexpressing
overexpressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07763614A
Other languages
German (de)
English (en)
Other versions
EP1986619A2 (fr
Inventor
Zhengping Zhuang
Edward H Oldfield
Deric M Park
Irina Lubensky
Jie Li
John S Kovach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of United States, a
Lixte Biotechnology Inc
Original Assignee
US Department of Health and Human Services
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Lixte Biotechnology Inc filed Critical US Department of Health and Human Services
Publication of EP1986619A2 publication Critical patent/EP1986619A2/fr
Publication of EP1986619A4 publication Critical patent/EP1986619A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP07763614A 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor Withdrawn EP1986619A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77116306P 2006-02-06 2006-02-06
US79720106P 2006-05-02 2006-05-02
PCT/US2007/003095 WO2007092414A2 (fr) 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Publications (2)

Publication Number Publication Date
EP1986619A2 EP1986619A2 (fr) 2008-11-05
EP1986619A4 true EP1986619A4 (fr) 2010-04-28

Family

ID=38345726

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07763614A Withdrawn EP1986619A4 (fr) 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Country Status (3)

Country Link
EP (1) EP1986619A4 (fr)
CA (1) CA2641308A1 (fr)
WO (1) WO2007092414A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
CN101854804B (zh) 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
AU2009277179A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010147612A1 (fr) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
WO2011097712A1 (fr) * 2010-02-11 2011-08-18 The Royal Institution For The Advancement Of Learning/Mcgill University Molécule hybride à la fois agoniste du récepteur de l'acide rétinoïque et inhibitrice de l'histone désacétylase
US10149847B2 (en) 2012-06-29 2018-12-11 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
CN105209036B (zh) 2013-04-09 2018-10-26 莱克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯的配制品
JP6453441B2 (ja) 2014-07-24 2019-01-16 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
CA2977256C (fr) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes et oxabicycloheptenes permettant de traiter des troubles depressifs et de stress
CN107708686B (zh) 2015-05-15 2021-02-19 莱克斯特生物技术公司 氧杂二环庚烷前药

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2002009680A2 (fr) * 2000-08-02 2002-02-07 Michael Walter Substance a activite pharmacologique, destinee au traitement de maladies cardio-vasculaires
WO2002028387A1 (fr) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibiteurs de l'angiogenese et de la croissance des tumeurs pour administration locale et systemique
WO2003092719A2 (fr) * 2002-04-29 2003-11-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procede et composition pour moduler la phosphorylation de la beta-catenine
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors
FR2872704A1 (fr) * 2004-07-12 2006-01-13 Laurent Schwartz Pluritherapie contre le cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2002009680A2 (fr) * 2000-08-02 2002-02-07 Michael Walter Substance a activite pharmacologique, destinee au traitement de maladies cardio-vasculaires
WO2002028387A1 (fr) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibiteurs de l'angiogenese et de la croissance des tumeurs pour administration locale et systemique
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors
WO2003092719A2 (fr) * 2002-04-29 2003-11-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procede et composition pour moduler la phosphorylation de la beta-catenine
FR2872704A1 (fr) * 2004-07-12 2006-01-13 Laurent Schwartz Pluritherapie contre le cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRASOR JONNA ET AL: "Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 37, September 2005 (2005-09-01), pages 13153 - 13157, XP002572866, ISSN: 0027-8424 *
HILL ET AL: "Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 12, 15 June 2007 (2007-06-15), pages 3392 - 3397, XP022097790, ISSN: 0960-894X *
KOK S-H ET AL: "Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio", CANCER LETTERS, NEW YORK, NY, US, vol. 217, no. 1, 10 January 2005 (2005-01-10), pages 43 - 52, XP004681287, ISSN: 0304-3835 *
LEE MI-OCK ET AL: "Role of coactivators and corepressors in the induction of the RARbeta gene in human colon cancer cells.", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 25, no. 10, October 2002 (2002-10-01), pages 1298 - 1302, XP002572865, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
WO2007092414A8 (fr) 2008-09-04
EP1986619A2 (fr) 2008-11-05
CA2641308A1 (fr) 2007-08-16
WO2007092414A3 (fr) 2008-05-15
WO2007092414A2 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
EP1986619A4 (fr) Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HK1245098A1 (zh) 治療慢性疼痛的方法
IL204541A0 (en) Use of mva to treat prostate cancer
HK1207578A1 (en) Treatment of synucleinopathies
EP2049139A4 (fr) Traitement de tumeurs exprimant ras
IL194198A0 (en) Administration of ketamine to treat depression
EP2370582A4 (fr) Traitement de maladies liées à un gène suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gène
EP2066589A4 (fr) Système de traitement de l'eau
EP2026843A4 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
EP2068864A4 (fr) Utilisations thérapeutiques d'urolithines
IL197315A0 (en) Treatment of cancer
EP2185173A4 (fr) Utilisation de phosphatases pour traiter des neuroblastomes et des médulloblastomes
EP1991230A4 (fr) Méthodes de traitement du cancer
ZA201008140B (en) Treatment of metastatic tumors
PL2274005T3 (pl) Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)
EP2300608A4 (fr) Procédés de traitement des tumeurs solides
PT2049127E (pt) Derivados n-metanocarba para tratamento de doenças cardíacas
EP1987838A4 (fr) Nouveau composé de traitement de tumeur
EP1986682A4 (fr) Procedes et compositions lies au ciblage de tumeurs et de plaies
EP1986660A4 (fr) Composés à base d'hexose pour traiter le cancer
HK1129601A1 (en) Compositions for contributing to the treatment of cancers
EP2056839A4 (fr) Approches combinées pour le traitement du cancer
ZA200902765B (en) Treatment of pulp
EP2043663A4 (fr) Traitement topique de verrues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080904

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOVACH, JOHN, S.

Inventor name: LI, JIE

Inventor name: LUBENSKY, IRINA

Inventor name: PARK, DERIC, M.

Inventor name: OLDFIELD, EDWARD, H.

Inventor name: ZHUANG, ZHENGPING

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA A

Owner name: LIXTE BIOTECHNOLOGY, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20100318BHEP

Ipc: A61K 31/00 20060101AFI20080912BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100330

17Q First examination report despatched

Effective date: 20110411

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20140610BHEP

Ipc: A61P 35/00 20060101ALI20140610BHEP

Ipc: A61K 31/00 20060101AFI20140610BHEP

INTG Intention to grant announced

Effective date: 20140703

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141114